Sababtoo ah kala-soocidda leukemia-ga iyo kala-soocidda saadaasha waa adag tahay, ma jiro hal-cabbir-qaab-daawaynta oo dhan, waxaana lagama maarmaan ah in la isku daro kala-saar taxaddar leh iyo saadaasha saadaasha si loo sameeyo qorshooyinka daaweynta. Waqtigan xaadirka ah, waxaa inta badan jira noocyada hababka daawaynta ee soo socda: kiimoterabiga, daaweynta shucaaca, daawaynta la beegsaday, immunotherapy, tallaalka unugyada stem, iwm.
Daawaynta dhamaystiran oo macquul ah, saadaasha cudurka leukemia ayaa si weyn loo hagaajiyay. Tiro aad u badan oo bukaanno ah ayaa la daweyn karaa ama waa la daweyn karaa waqti dheer. Waagii leukemia oo ahaa "cudur aan laga bogsan karin" waa la soo dhaafay.
Daawaynta AML (aan ahayn M3)
Caadi ahaan waa lagama maarmaan in marka hore la sameeyo kiimiko isku dhafan, waxa loogu yeero "kemotherabi induction", oo caadi ahaan loo isticmaalo nidaamka DA (3 + 7). Daawaynta induction ka dib, haddii cafis la helo, kimoterabi-isku-darka xooggan oo dheeraad ah ama hababka tallaalka unugyada tarma ayaa la sii wadi karaa iyadoo loo eegayo habaynta saadaasha. Daaweynta xoojinta ka dib, daaweynta dayactirka badanaa lama sameeyo hadda, daawada waa la joojin karaa si loo eego oo si joogto ah loola socdo.
daawaynta M3
Sababtoo ah guusha daawaynta la beegsaday iyo daaweynta apoptosis ee la kiciyay, PML-RARA togan acute promyelocytic leukemia (M3) ayaa noqotay nooca ugu fiican ee saadaalinta guud ahaan AML. Daraasado aad iyo aad u badan ayaa muujiyay in all-trans retinoic acid oo ay weheliso daawaynta arsenic ay daweyn karto badi bukaannada qaba M3. Daaweyntu waxay u baahan tahay in si adag loo fuliyo iyadoo la raacayo habka daawaynta, iyo dhererka daawaynta dayactirka ee xilliga dambe waxaa inta badan lagu go'aamiyaa xaaladda hadhaaga ee hidde-wadaha fiyuuska.
DHAMMAAN daawaynta
Kemotherabi induction waxaa badanaa la sameeyaa marka hore, waxaana jira kala duwanaansho hababka caadiga ah ee la isticmaalo ee u dhexeeya dadka waaweyn iyo carruurta. Si kastaba ha ahaatee, sannadihii ugu dambeeyay, cilmi-baaristu waxay soo jeedisay in natiijooyinka isticmaalka hababka carruurta ee lagu daweeyo bukaannada qaangaarka ah ay ka fiicnaan karaan hababka dadka waaweyn ee dhaqameed. Ka dib cafiska, waa lagama maarmaan in lagu adkaysto xoojinta iyo daaweynta dayactirka. Bukaannada khatarta sare leh waxay leeyihiin shuruudo lagu beddelo unugyada asliga ah. Bukaannada qaba chromosome-ka togan ee Ph1 waxaa lagula talinayaa in lagu daweeyo tyrosine kinase inhibitors.
Daawaynta Cudurka Kansarka ee Myelogenous
Marxaladda dabadheeraad ah, tyrosine kinase inhibitors (sida imatinib) ayaa ah daaweynta la doorbido. Waxaa lagu talinayaa in lagu daweeyo sida ugu dhakhsaha badan iyo xaddi ku filan. Isticmaalka daahista iyo isticmaalka joogtada ah waxay si fudud u horseedi karaan caabbinta daroogada. Sidaa darteed, haddii aad go'aansato inaad isticmaasho imatinib, marka hore, dib ha u dhigin, marka labaadna, waa inaad ku adkaysataa isticmaalka muddada dheer (noolaha u dhow), oo ha iska dhimin qadarka ama joojinta qaadashada markaad qaadanayso, haddii kale. waxay si fudud u horseedi doontaa caabbinta daroogada. Marxaladda la dedejiyey iyo marxaladda ba'an waxay caadi ahaan u baahan tahay daaweyn la beegsaday (imatinib qaadashada ama isticmaalka dawooyinka jiilka labaad). Haddii ay suurtagal tahay, tallaalka allogeneic ama daaweynta isku dhafka waqtiga waa la aqbali karaa.
Daaweynta lymphocyte daba-dheeraada
Bukaannada asymptomatic-ka hore caadi ahaan uma baahna daaweyn, iyo marxaladda dambe, waxay dooran karaan noocyo kala duwan oo daawaynta kiimiko ah, sida Liu Keran monotherapy, fludarabine, cyclophosphamide oo lagu daray merova, iyo kiimoterabi kale. Bendamustine iyo ka-hortagga CD52 monoclonal antibodies ayaa sidoo kale waxtar leh. Sanadihii la soo dhaafay, waxaa la ogaaday in daawaynta bartilmaameedka ah ee ka hortagga dariiqa BCR ay saameyn weyn ku yeelan karto. Bukaan-socodka qaba xaaladaha dib-u-celinta waxay tixgelin karaan daaweynta allograft.
Daawaynta habka dhexe ee neerfayaasha leukemia
Inkasta oo noocyada M4 iyo M5 ee DHAMMAAN iyo AML inta badan lagu daro CNSL, leukemias kale oo ba'an ayaa sidoo kale dhici kara. Sababtoo ah dawooyinka caadiga ah ee la isticmaalo way adagtahay in la galo xannibaadda dhiigga-maskaxda, bukaannadani waxay caadi ahaan u baahan yihiin daloolin lumbar si looga hortago oo loo daweeyo CNSL. Bukaanjiifka qaar ayaa laga yaabaa inay u baahdaan shucaaca xudunta laf dhabarta ee maskaxda oo dhan.
Marka laga reebo dhowr bukaan oo gaar ah oo laga yaabo inay ka faa'iidaystaan tallaalka iswada (heerka soo noqnoqda ku-tallaalidda iswada-taagga ah waa mid aad u sarreeya), badi bukaannada leukemia waa inay doortaan xenotransplantation for transplantation.
Marka la soo koobo, daawaynta guud ee safka kowaad ee leukemia ma aha bedel. Inkasta oo ku-tallaalidda ay heli karto saameyn badbaado oo ka wanaagsan, dhibaatooyinka sida heerka soo noqnoqda iyo cudurka tallaalka-ka-horjeedka- martida loo yahay ayaa si weyn u saameyn kara tayada nolosha bukaanka. Daawaynta ka dib soo noqoshada waxay noqon doontaa mid aad u adag. Sidaa darteed, ku-tallaalid guud ahaan waa tallaabada ugu dambeysa ee doorashada.
